Celgene (CELG) Granted FDA Priority Review for ABRAXANE sNDA in Advanced Pancreatic Cancer
Tweet Send to a Friend
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that the U.S. Food and Drug Administration (FDA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


